Pain medication use in patients with X-linked hypophosphatemia treated with burosumab: a retrospective real-world study.

Carolyn M Macica¹, Zhiyi Li², Ben Johnson³, Ahmed Noman⁴, Catherine Park⁴, Gina N Woods⁵

¹University of Connecticut School of Medicine and Connecticut Children's Research Institute, Department of Research Operations and Development, Hartford, CT 06106, United States.

²Kyowa Kirin Inc., HEOR, Princeton, NJ 08540, United States.

³Kyowa Kirin International, HEOR, Marlow SL7 1HZ, United Kingdom.

⁴Komodo Health Inc., New York, NY 10010, United States.

⁵UC San Diego Health, School of Medicine, CA 92093-0602, United States.

PubMed PMC DOI PDF

Abstract

X-linked hypophosphatemia (XLH) is a rare, progressive phosphate-wasting disorder that leads to significant skeletal morbidity and pain. The current study used real-world administrative claims data to assess the demographic and clinical characteristics of patients with XLH related to claims for prescription pain medication (PPM) during the 12 mo before starting burosumab treatment (baseline) and e…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.